Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Avatar: Personalized Precision Radio-Genomic Theranostic Oncology.

Cancer biotherapy & radiopharmaceuticals·2025

Same author

Intuitive Human-Artificial Intelligence Theranostic Complementarity.

Cancer biotherapy & radiopharmaceuticals·2025

Same author

Human-Artificial Intelligence Symbiotic Reporting for Theranostic Cancer Care.

Cancer biotherapy & radiopharmaceuticals·2024

Same author

Theranostics, Advanced Cancer, and The Meaning of Life.

Cancer biotherapy & radiopharmaceuticals·2024

Same author

Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients.

Cancer biotherapy & radiopharmaceuticals·2024

Same author

Triangle of Trust in Cancer Care? The Physician, the Patient, and Artificial Intelligence Chatbot.

Cancer biotherapy & radiopharmaceuticals·2023

Search research articles

Related Experiment Video

Updated: Jun 26, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Theranostics: Timing is Everything.

J Harvey Turner¹

¹Department of Nuclear Medicine, Fiona Stanley Fremantle Hospitals Group, The University of Western Australia, Murdoch, Australia.

Cancer Biotherapy & Radiopharmaceuticals

|May 17, 2024

Summary

This summary is machine-generated.

Timing is crucial for advancing molecular targeted radioligand therapy in cancer care. Precision dosing and combination treatments are key for effective theranostics, marking a new era in nuclear medicine.

Keywords:

dosimetry phronesis radioligand FAPI pancreas cancer therapy sequencing theranostic nuclear medicine

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Jun 26, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

Area of Science:

Nuclear medicine and oncology
Molecular targeted radioligand therapy
Theranostics in cancer care

Background:

Nuclear medicine's therapeutic origins in thyroid cancer treatment with radioiodine.
Resurgence of physician roles in nuclear medicine driven by PSMA-targeted radioligands (Ga-68/Lu-177/Ac-225).
Evolving landscape of cancer care emphasizing precise timing in molecularly targeted therapies.

Discussion:

Urgent need for workforce training in -omics expertise and clinical application of theranostics.
Importance of individualized dosimetry (radiation absorbed dose in Gy) for tumor and critical organs.
Critique of fixed-activity (GBq) administration and arbitrary treatment intervals.

Key Insights:

Theranostic cancer care hinges on optimal timing for molecularly targeted radioligand therapy.
Individualized radiation absorbed dose (Gy) is essential for precision radioligand therapy.
Combination sequenced theranostic-immuno-chemotherapeutic strategies are needed for metastatic cancers.

Outlook:

Potential for fibroblast activation protein inhibitor (FAPI) radioligands to target the tumor microenvironment.
Improved public perception of nuclear medicine ('nuclear is the new green').
Favorable circumstances for the future development and clinical integration of theranostics.